PTC Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell PTCT and other ETFs, options, and stocks.

About PTCT

PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in Warren, NJ. 

CEO
Matthew B. Klein
CEOMatthew B. Klein
Employees
939
Employees939
Headquarters
Warren, New Jersey
HeadquartersWarren, New Jersey
Founded
1998
Founded1998
Employees
939
Employees939

PTCT Key Statistics

Market cap
3.67B
Market cap3.67B
Price-Earnings ratio
-9.85
Price-Earnings ratio-9.85
Dividend yield
Dividend yield
Average volume
1.08M
Average volume1.08M
High today
$51.43
High today$51.43
Low today
$46.37
Low today$46.37
Open price
$50.78
Open price$50.78
Volume
2.87M
Volume2.87M
52 Week high
$58.38
52 Week high$58.38
52 Week low
$24.00
52 Week low$24.00

PTCT News

TipRanks 4d
Cautious Hold Rating on PTC Therapeutics Amid Regulatory Challenges and Pipeline Developments

Tazeen Ahmad, an analyst from Bank of America Securities, maintained the Hold rating on PTC Therapeutics (PTCT – Research Report). The associated price target r...

TipRanks 4d
Strategic Resilience and Growth Potential: A Buy Rating for PTC Therapeutics Amid Regulatory Challenges

Morgan Stanley analyst Judah Frommer maintained a Buy rating on PTC Therapeutics (PTCT – Research Report) yesterday and set a price target of $70.00. Judah Fro...

TipRanks 4d
PTC Therapeutics: Strategic Growth and Market Expansion Justify Buy Rating Amid Regulatory Challenges

William Blair analyst Sami Corwin has maintained their bullish stance on PTCT stock, giving a Buy rating on March 14. Sami Corwin has given his Buy rating due...

Analyst ratings

53%

of 15 ratings
Buy
53.3%
Hold
33.3%
Sell
13.3%

More PTCT News

TipRanks 5d
PTC Therapeutics Faces EU Setback on Translarna

PTC Therapeutics ( (PTCT) ) has issued an announcement. On March 28, 2025, PTC Therapeutics announced that the European Commission adopted the negative opinion...

Benzinga 5d
European Commission Declines To Renew Marketing Authorization Of Translarna Duchenne Muscular Disorder

The European Commission (EC) adopted the opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) not to rene...

European Commission Declines To Renew Marketing Authorization Of Translarna Duchenne Muscular Disorder
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.